PLGA-PEG-COOH from PolySciTech used in development of sialyl-Tn targeted drug-delivery system for treatment of gastric cancer

 

Gastric cancer is a disease in which a tumor forms within the stomach or gastric chambers and is the fourth leading cause of cancer-related deaths worldwide. Researchers at Universidade do Porto (Portugal) used PLGA-PEG-COOH (cat# AI076) from PolySciTech division of Akina, Inc. (www.polyscitech.com) to create Sialyl-Tn targeted nanoparticles for delivery of active pharmaceutical, Foretinib. This research holds promise to provide for improved therapy against gastric cancer in the future. Read more: Diniz, Francisca, Sofia Lamas, Hugo Osório, Paulo Aguiar, Daniela Freitas, Fátima Gartner, Bruno Sarmento, Celso A. Reis, and Joana Gomes. "Nanoparticles targeting Sialyl-Tn for efficient tyrosine kinase inhibitor delivery in gastric cancer." Acta Biomaterialia (2023). https://www.sciencedirect.com/science/article/pii/S1742706123004695

“Abstract: Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide and, therefore, it is urgent to develop new and more efficient therapeutic approaches. Foretinib (FRT) is an oral multikinase inhibitor targeting MET (hepatocyte growth factor receptor) and RON (recepteur d'origine nantais) receptors tyrosine kinases (RTK) that has been used in clinical trials for several solid tumors. Targeted uptake of therapeutic polymeric nanoparticles (NPs) represents a powerful approach in cancer cell drug delivery. Previously, a nanodelivery system composed of polymeric NPs functionalized with B72.3 antibody, which targets the tumor-associated antigen Sialyl-Tn (STn), has been developed. Herein, these NPs were loaded with FRT to evaluate its capacity in delivering the drug to multicellular tumors spheroids (MCTS) and mouse models. The data indicated that B72.3 functionalized FRT-loaded PLGA-PEG-COOH NPs (NFB72.3) specifically target GC MCTS expressing the STn glycan (MKN45 SimpleCell (SC) cells), leading to a decrease in phospho RTK activation and reduced cell viability. In vivo evaluation using MKN45 SC xenograft mice revealed that NFB72.3 were able to decrease tumor growth, reduce cell proliferation and tumor necrosis. NFB72.3-treated tumors also showed inactivation of phospho-MET and RON. This study demonstrates the value of using NPs targeting STn for FRT delivery, highlighting its potential as a therapeutic application in GC.”